000	00000nam 2200000zi 4500
001	9.919396
003	CaOODSP
005	20230302165704
006	m     o  d f
007	cr mn|||||||||
008	230124e202302##oncd    ob   f000 0 eng d
020	|a9780660472331
040	|aCaOODSP|beng|erda|cCaOODSP
043	|an-cn---
086	1 |aHP5-154/2023E-PDF
245	00|aRecommendations on the use of conjugate pneumococcal vaccine - 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults : |beconomic evidence supplementary appendix.
264	1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cFebruary 2023.
264	4|c©2023
300	|a1 online resource (44 pages) : |bgraphs
336	|atext|btxt|2rdacontent
337	|acomputer|bc|2rdamedia
338	|aonline resource|bcr|2rdacarrier
500	|aIssued also in French under title: Recommandations sur l'utilisation du vaccin conjugué 15-valent (PNEU-C-15) contre le pneumocoque et 20-valent (PNEU-C-20) contre le pneumocoque chez les adultes : annexe de données économiques supplémentaires.
500	|aOn cover: An advisory committee statement (ACS), National Advisory Committee on Immunization (NACI).
500	|a"Pub.: 220714."
504	|aIncludes bibliographical references (pages 38-44).
650	0|aPneumococcal vaccine|zCanada.
650	0|aVaccines|xEconomic aspects|zCanada.
710	2 |aPublic Health Agency of Canada, |eissuing body.
710	1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body.
775	08|tRecommandations sur l'utilisation du vaccin conjugué 15-valent (PNEU-C-15) contre le pneumocoque et 20-valent (PNEU-C-20) contre le pneumocoque chez les adultes : |w(CaOODSP)9.919397
856	40|qPDF|s1.87 MB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP5-154-2023-eng.pdf
856	4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/economic-evidence-supplementary-appendix.html